A blood test that could help diagnose Alzheimer’s disease sounds simple.
One sample. One result. An answer.
That is the promise attracting enormous interest in dementia research.
Scientists have made significant progress in identifying substances in the blood that reflect biological changes associated with Alzheimer’s disease. Among the most promising is a protein known as phosphorylated tau 217, or p-tau217.
Recent studies suggest that some blood tests measuring p-tau217 can identify Alzheimer’s-related brain pathology with high accuracy.
But this is also an area where headlines can run ahead of clinical practice.
At present, there is an important difference between a promising Alzheimer’s blood biomarker and a routine diagnostic or screening test available to everyone in the UK.
They are not yet the same thing.
So what can these blood tests actually tell us, how accurate are they, and are they currently part of NHS dementia diagnosis?
What Are Alzheimer’s Blood Tests?
Alzheimer’s blood tests are designed to measure biological markers associated with changes occurring in the brain.
Researchers are particularly interested in markers associated with amyloid and tau, two proteins closely linked with Alzheimer’s disease.
Several potential blood biomarkers are being studied, including:
- phosphorylated tau 217, or p-tau217
- p-tau181
- p-tau231
- amyloid-beta proteins
- neurofilament light, or NfL
- glial fibrillary acidic protein, or GFAP.
Of these, p-tau217 has emerged as one of the most promising for identifying Alzheimer’s-related pathology.
These tests are very different from the standard blood tests a GP may currently arrange when investigating memory difficulties.
Routine blood tests usually look for other conditions that could contribute to cognitive symptoms, such as thyroid problems, vitamin deficiencies, liver or kidney disease and diabetes.
An Alzheimer’s biomarker blood test is instead looking for biological changes associated with the disease itself.
Why Are Alzheimer’s Blood Tests Attracting So Much Attention?
Diagnosing Alzheimer’s disease can be complicated.
There is currently no single standard test that can diagnose dementia on its own.
According to NHS guidance, dementia assessment may involve several different sources of information, including:
- a detailed medical and symptom history
- information about changes in memory and daily functioning
- cognitive testing
- physical examination
- blood tests to investigate other possible causes
- brain imaging where appropriate
- specialist investigations in selected cases.
NICE guidance similarly recommends considering cognitive, behavioural and psychological symptoms alongside how they affect everyday life.
Potentially reversible causes of cognitive difficulties should also be investigated.
More specialist Alzheimer’s investigations can involve cerebrospinal fluid testing or specialised brain imaging, such as PET scans, in selected cases.
These investigations can be clinically useful, but some are expensive, invasive or not easily accessible.
A reliable blood test could potentially make Alzheimer’s assessment:
- quicker
- less invasive
- more accessible
- less expensive
- easier to integrate into memory-clinic pathways.
That is why blood biomarkers have become such an important area of dementia research.
What Is p-tau217?
Tau is a protein naturally found inside nerve cells.
In Alzheimer’s disease, abnormal changes to tau occur alongside the build-up of amyloid proteins in the brain.
Researchers can measure different forms of phosphorylated tau in the blood.
One of these is p-tau217.
Levels of p-tau217 tend to increase when Alzheimer’s-related amyloid and tau pathology is present in the brain.
This means that p-tau217 may act as a biological signal that Alzheimer’s disease processes are occurring.
It does not, however, mean that every person with an abnormal result has dementia.
That distinction is extremely important.
How Accurate Are Alzheimer’s Blood Tests?
The evidence has become increasingly encouraging.
A major systematic review and meta-analysis published in The Lancet Neurology in 2025 analysed 113 studies involving almost 30,000 participants.
Among the blood biomarkers assessed, p-tau217 showed the strongest performance.
The pooled results indicated approximately:
- 88% sensitivity
- 89% specificity
for identifying biologically defined Alzheimer’s disease.
Sensitivity refers to how well a test identifies people who have the relevant disease pathology.
Specificity describes how well a test correctly identifies people who do not.
Other systematic reviews and meta-analyses have also reported strong diagnostic performance for p-tau217.
This makes it one of the most promising Alzheimer’s biomarkers currently being investigated.
However, even a test with sensitivity and specificity approaching 90% is not perfect.
False-positive and false-negative results can still occur.
Performance can also vary depending on:
- the specific test or assay
- the laboratory
- the population being tested
- the stage of disease
- whether cognitive symptoms are already present
- other medical conditions
- the threshold used to define an abnormal result.
This is why blood-test results should not be interpreted in isolation.
Can A Blood Test Diagnose Alzheimer’s Disease On Its Own?
In routine UK clinical practice, no.
NHS guidance continues to state that there is no single test for dementia.
Diagnosis requires a combination of clinical assessment, cognitive evaluation and appropriate investigations.
Blood biomarkers may eventually become an important component of this process.
But they do not currently replace the need to understand:
- what symptoms someone is experiencing
- how symptoms have developed
- whether everyday functioning has changed
- whether another physical or psychiatric condition could explain the symptoms
- what cognitive assessment shows
- what other investigations reveal.
A laboratory result cannot provide all of this information.
Are Alzheimer’s Blood Tests Available On The NHS?
Blood biomarkers are progressing rapidly towards clinical implementation, but they are not yet a universal routine NHS test for diagnosing Alzheimer’s disease.
Several major UK research programmes are investigating how these tests could be incorporated safely into NHS memory services.
One example is the ADAPT study, which is assessing whether p-tau217 testing can improve diagnosis within NHS memory clinics.
The research is examining whether the blood test could help clinicians decide who may benefit from further specialist investigations and potentially make diagnostic pathways more efficient.
Researchers at the University of Oxford and elsewhere in the UK are also studying combinations of blood and digital biomarkers with the aim of improving dementia diagnosis.
Importantly, researchers are not simply asking whether these tests work.
They are also asking:
- Which test should be used?
- Which patients should receive it?
- At what point in an assessment should it be performed?
- What result should count as positive?
- How should borderline results be managed?
- Do the tests work equally well across different populations?
- Will using the tests actually improve patient care?
These questions need to be answered before biomarker testing becomes a universal part of routine clinical practice.
Can A Blood Test Tell You Whether You Will Develop Dementia?
Not reliably in routine clinical practice.
Research is exploring whether biomarkers can detect Alzheimer’s-related biological changes before symptoms become obvious.
That does not mean there is currently a validated blood test capable of telling a healthy person with certainty whether they will develop dementia years in the future.
No current blood test can reliably answer:
“Will I develop dementia in 10 or 20 years?”
for an individual person with certainty.
The UK National Screening Committee does not currently recommend population screening for dementia.
This distinction is important.
Testing somebody who already has persistent cognitive symptoms as part of a clinical assessment is different from screening healthy people who have no symptoms.
What Is The Difference Between Alzheimer’s Disease And Dementia?
Alzheimer’s disease and dementia are often used interchangeably, but they do not mean exactly the same thing.
Dementia describes a group of symptoms involving an ongoing decline in cognitive abilities that becomes significant enough to interfere with everyday functioning.
Alzheimer’s disease is one of several diseases that can cause dementia and is the most common cause.
Other causes include:
- vascular dementia
- dementia with Lewy bodies
- frontotemporal dementia
- mixed dementia.
This is another reason a positive Alzheimer’s biomarker does not automatically provide a complete clinical diagnosis.
A clinician still needs to understand the person’s symptoms, their progression and whether another condition could provide a better explanation.
Does An Abnormal Alzheimer’s Blood Test Mean Someone Has Dementia?
Not necessarily.
Biological changes associated with Alzheimer’s disease may begin years before dementia develops.
Someone can potentially have evidence of Alzheimer’s-related pathology while remaining independent in everyday life.
Conversely, someone may have significant cognitive symptoms caused by something other than Alzheimer’s disease.
This means that diagnosis cannot rely only on the presence of a biomarker.
A full assessment considers:
- symptoms
- cognitive functioning
- everyday abilities
- physical health
- medication
- mental health
- neurological findings
- other investigations.
The clinical context remains essential.
What Else Can Cause Memory Problems?
Memory problems do not automatically mean dementia.
A number of other conditions can affect memory and concentration.
These include:
- depression
- anxiety
- prolonged stress
- poor-quality sleep
- medication side effects
- alcohol or drug use
- thyroid disorders
- vitamin B12 or folate deficiency
- infections
- delirium
- other neurological conditions.
Some causes of memory difficulty are treatable.
This is one reason it is better to seek a proper assessment than either assuming symptoms are “just ageing” or assuming they definitely mean dementia.
What Memory Changes Should Be Assessed?
Occasional forgetfulness can happen to anyone.
For example, many people sometimes:
- forget a name and remember it later
- misplace keys or another item
- forget an appointment
- take longer to learn an unfamiliar task.
These experiences alone do not necessarily indicate dementia.
Changes become more concerning when they are persistent, progressively worsening or beginning to interfere with everyday life.
Examples may include:
- repeatedly forgetting recent conversations
- asking the same question many times
- becoming lost in familiar locations
- difficulty managing bills or finances
- problems taking medication correctly
- struggling with familiar tasks
- frequent difficulty finding ordinary words
- confusion about time or place
- significant changes in judgement or behaviour.
The pattern of change and its effect on daily functioning are more important than one isolated episode of forgetfulness.
What Happens During A Memory Assessment?
A proper memory assessment involves much more than taking a short memory test.
NICE recommends obtaining a history from the person and, where appropriate, information from somebody who knows them well.
Clinicians may consider:
- memory symptoms
- other cognitive changes
- mood and behaviour
- ability to perform everyday activities
- physical health
- medication
- alcohol and substance use
- vision and hearing
- potentially reversible causes.
Cognitive assessment may also be carried out using validated tools.
Importantly, NICE advises clinicians not to exclude dementia simply because someone performs normally on a brief cognitive assessment.
Further investigations may include blood tests and brain imaging.
Specialist investigations may be appropriate where the diagnosis remains uncertain and where the results could change treatment or management.
Could Alzheimer’s Blood Tests Replace PET Scans Or Lumbar Punctures?
Possibly for some people in the future.
This is one of the most exciting potential uses of blood biomarkers.
If sufficiently accurate, blood tests could eventually be used as an initial triage tool.
For example, they may help clinicians identify people who are:
- unlikely to have Alzheimer’s-related pathology
- more likely to require further specialist assessment
- appropriate for more expensive or invasive confirmatory testing.
However, different commercial tests do not all perform identically.
Validation, laboratory quality and interpretation remain extremely important.
Blood biomarkers should therefore be viewed as emerging clinical tools rather than a universal replacement for current diagnostic methods.
Why Does Earlier And More Accurate Diagnosis Matter?
Receiving a timely diagnosis can help people understand what is happening and make informed decisions.
A diagnosis may:
- explain the reason for cognitive symptoms
- identify alternative and potentially treatable conditions
- improve access to treatment
- provide access to support
- help families understand changing needs
- allow planning for the future
- reduce uncertainty.
Earlier and more accurate diagnosis may become increasingly important as research continues into treatments designed to target specific biological changes associated with Alzheimer’s disease.
However, earlier testing only provides meaningful benefit when it is accompanied by appropriate counselling, clinical interpretation, treatment and support.
Should You Buy A Private Alzheimer’s Blood Test Online?
Caution is advisable.
A commercially available blood test is not automatically equivalent to a well-validated test used within a specialist clinical pathway.
Before considering a private Alzheimer’s biomarker test, useful questions include:
- Has this specific test been independently validated?
- What biomarker does it actually measure?
- Is it intended for people with symptoms or for screening healthy people?
- Who will interpret the result?
- What happens if the result is uncertain?
- Will the result change clinical management?
- Has the test been validated in people similar to you?
- Will you have access to appropriate clinical counselling afterwards?
A test result without appropriate clinical context can create unnecessary anxiety.
It could also create false reassurance if the result is interpreted incorrectly.
For someone who is concerned about memory changes, a comprehensive assessment is generally more useful than ordering an isolated test without specialist interpretation.
Should People Without Symptoms Have An Alzheimer’s Blood Test?
Routine dementia screening is not currently recommended in the UK.
The UK National Screening Committee does not recommend population screening for dementia.
This does not mean biomarker research lacks value.
It means there is currently insufficient evidence to recommend routinely testing everyone without symptoms when the implications, benefits and potential harms of doing so remain uncertain.
Screening and diagnosis should not be confused.
Someone who already has persistent memory or cognitive symptoms should seek professional assessment.
For a related evidence review, read Can Brain Training Reduce Dementia Risk? What the Latest Research Shows.
When Should You Seek Professional Advice?
Speak to your GP or an appropriately qualified specialist if memory or thinking problems:
- are becoming progressively worse
- interfere with work or everyday activities
- affect management of money or medication
- lead to becoming lost in familiar places
- are noticeable to relatives or close friends
- involve changes in language
- affect judgement or behaviour
- are causing significant concern.
A sudden change in mental state should be treated differently from gradually developing memory symptoms.
Sudden confusion may represent delirium, infection, medication effects or another acute medical condition and should receive prompt medical assessment.
How Oxford Psychiatry Group Can Help
Oxford Psychiatry Group provides specialist assessment for memory difficulties, cognitive change and dementia through its older-adult psychiatry services.
Learn more about Dr Michelle Hutchinson, one of Oxford Psychiatry Group’s specialists in old age psychiatry and cognitive disorders.
A comprehensive assessment considers much more than one test result.
Depending on individual circumstances, assessment may include:
- detailed clinical history
- cognitive assessment
- review of physical health
- review of mental health
- medication review
- information from relatives or carers where appropriate
- recommendations for further investigations
- discussion of diagnosis, treatment and ongoing support.
The purpose of assessment is not simply to determine whether somebody “passes” or “fails” a memory test.
It is to understand what has changed, why it may be happening and what the most appropriate next step should be.
If you are concerned about memory changes in yourself or someone close to you, seeking an appropriate clinical assessment can provide clarity and help identify the next steps. You can also book an initial consultation with Oxford Psychiatry Group.
Frequently Asked Questions
Is There Now A Blood Test For Alzheimer’s Disease?
There are promising blood biomarker tests for Alzheimer’s disease, particularly tests measuring p-tau217.
However, they are not yet a standalone routine diagnostic test for everyone in UK clinical practice.
What Does p-tau217 Mean?
P-tau217 is a phosphorylated form of the tau protein.
Increased levels in blood are strongly associated with amyloid and tau pathology related to Alzheimer’s disease.
How Accurate Is p-tau217?
A major 2025 systematic review and meta-analysis reported pooled sensitivity of approximately 88% and specificity of approximately 89% for identifying biologically defined Alzheimer’s disease.
Performance can vary depending on the exact test, population and clinical setting.
Can I Ask My GP For An Alzheimer’s Blood Test?
Routine GP blood tests for memory problems currently mainly investigate other potentially treatable causes of cognitive symptoms.
Alzheimer’s-specific biomarker blood testing is still being evaluated and introduced through research and specialist pathways rather than being universally available throughout routine NHS care.
Can A Blood Test Tell Me Whether I Will Get Dementia?
Not reliably.
Research into predicting future Alzheimer’s disease is ongoing, but population screening for dementia is not currently recommended in the UK.
A biomarker cannot currently tell an individual with certainty whether they will develop dementia years in the future.
Does A Positive Alzheimer’s Biomarker Mean I Have Dementia?
No.
A biomarker can indicate biological changes associated with Alzheimer’s disease, but these findings must be interpreted alongside symptoms, cognitive functioning and a wider clinical assessment.
Can Memory Problems Be Caused By Something Other Than Dementia?
Yes.
Depression, anxiety, sleep difficulties, stress, medication, alcohol, thyroid problems, vitamin deficiencies and several other medical conditions can contribute to memory difficulties.
Do Normal Memory Test Results Rule Out Dementia?
Not necessarily.
NICE specifically advises against ruling out dementia solely because somebody performs normally on a brief cognitive assessment.
Clinical history and changes in everyday functioning remain important.
The Bottom Line
Blood tests for Alzheimer’s disease are moving rapidly from research towards clinical practice.
Among the most promising is p-tau217, which has demonstrated strong accuracy for identifying Alzheimer’s-related biological changes in large studies.
This represents an important scientific advance.
But it does not mean Alzheimer’s or dementia diagnosis has been reduced to a single blood test.
In the UK, diagnosis still requires clinical judgement, cognitive assessment, investigation of other potential causes and appropriate specialist testing where necessary.
The most responsible approach is therefore neither to dismiss these new blood tests nor to exaggerate what they can currently do.
They may become an important part of dementia diagnosis.
For now, they should be understood as promising diagnostic tools that may form part of a wider clinical assessment rather than as a standalone answer or routine screening test for everyone.
If you or somebody close to you is experiencing persistent changes in memory, thinking, language or everyday functioning, seeking an appropriate clinical assessment remains the most useful first step.
References
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers (NG97).
- NHS. Tests for diagnosing dementia.
- NHS. Alzheimer’s disease: diagnosis.
- UK National Screening Committee. Dementia screening recommendation. Reviewed 2026.
- Therriault J, Brum WS, Trudel L, et al. Blood phosphorylated tau for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. The Lancet Neurology. 2025;24(9):740–752.
- Khalafi M, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer’s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis. Alzheimer’s & Dementia. 2025;21(2):e14458.
- Alzheimer’s Society. UK trial launches to transform Alzheimer’s diagnosis with simple blood test. 2025.
- Alzheimer’s Society. A faster and fairer dementia diagnosis using blood tests and digital tools. University of Oxford research project. 2026.
- Alzheimer’s Society. World Alzheimer’s Month.
- Royal College of Psychiatrists. The Old Age Psychiatrist, Issue 95. Blood biomarkers in Alzheimer’s disease. 2026.
Medical Disclaimer
This article is intended for general information and education only. It does not provide a diagnosis and does not replace individual medical advice, assessment or treatment.
If you are concerned about memory, cognitive change or another health problem, speak to an appropriately qualified healthcare professional.
